GSK Seeks Manufacturing Partners For Flu Treatment Relenza
This article was originally published in The Pink Sheet Daily
Executive Summary
The antiviral’s inhaler system may pose manufacturing hurdles for third parties, CEO Garnier concedes.
You may also be interested in...
Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
German firm will pay $102 mil. for rights to develop and commercialize Biota’s novel nucleoside analogues for hepatitis C.
Boehringer Ingelheim Bolsters HCV Research Portfolio With Biota Deal
German firm will pay $102 mil. for rights to develop and commercialize Biota’s novel nucleoside analogues for hepatitis C.
Chiron Inks $62.5 Mil. Avian Flu Vaccine Deal With HHS
HHS Secretary Leavitt looks to cell culture-based technology for more rapid vaccine production in case of future pandemics.